Download May 13, 2015

Media Contacts
Carol Berry, MBA
Chief Business Officer, SVP
Caprion
[email protected]
514.360.3600
Caprion/ImmuneCarta Highlights Data Presented by Adaptimmune at the 2015
American Society of Gene and Cell Therapy Annual Meeting
Enhanced-affinity NY-ESO-1-specific T cells exhibit extended functionality without exhaustion in a
pattern of effector and memory programming in multiple cancer indications
Montreal, Canada – May 13, 2015— Caprion announced today that Adaptimmune will present data at
the American Society of Gene and Cell Therapy Annual Meeting on Friday May 15th in the
Immunotherapy Session from 3:30pm- 5:30pm.
Adaptimmune is conducting Phase 1/2 clinical trials for its NY-ESO TCR therapeutic in cancer patients
including patients with synovial sarcoma and multiple myeloma. Affinity enhanced T cells specific for the
NY-ESO-1 cancer testis antigen were administered to patients with synovial sarcoma and multiple
myeloma. The data being presented relates to the phenotypic and functional evaluation of the
engineered T cells administered to patients and the data may suggest that the engineered autologous T
cells administered can expand and persist in patients without exhibiting signs of T cell exhaustion. Yoav
Peretz, Ph.D., Scientific Director at Caprion’s ImmuneCarta Division said, “We are privileged to work with
Adaptimmune in these pioneering studies in the field of Immuno Oncology and excited by the potential
for our ImmuneCarta assays to help further the understanding of immune correlates of protection.”
Martin LeBlanc, CEO of Caprion, stated, “These results provide another tangible illustration of Caprion’s
ability to collaborate with leading biotech and pharma companies and to deliver valuable immunological
insights in support of their clinical development objectives.”
About Caprion
Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical
and biotechnology industry. Its immune monitoring business unit, ImmuneCartaTM, offers proprietary
multi-parametric flow cytometry for functional analyses of innate and adaptive immune responses.
Caprion’s proteomics business unit, ProteoCarta®, offers proprietary gel-free, label-free mass
spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins
across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion
also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic
and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has
been providing large-scale proteomics and immune monitoring services to over 50 major
pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is
majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.